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have unlimited replicative potential via the upregulation 
of telomerase (a specialized deoxyribonucleic acid (DNA) 
polymerase) expression that counters telomerase erosion 
(Fig. 1) [4].
In addition, cancer cells have the ability to evade tumor 
suppressor genes, resulting in sustained chronic prolifera-
tion. These cells may avoid apoptosis induction by the loss 
of protein p53 (TP53) tumor suppressor function, or in the 
case of necrosis, proinflammatory signals that recruit cells 
of the immune system, which may promote malignancy 
and invasion [3, 5]. Cancer cells may also produce their 
own growth factor ligands such as Bombesin-like peptides 
(secreted by human small cell lung cancer) or signal to 
non-tumorigenic surrounding tissue to supply cancer cells 
with growth factors (Fig. 1) [6]. These cells may activate 
invasion and metastasis by developing alterations in shape 
and attachment to the extracellular matrix and neighboring 
cells (Fig. 1) [3].
Tumorigenic cells can induce angiogenesis by upregula-
tion of vascular endothelial growth factors, such as vascular 
endothelial growth factor A (VEGF-A) by either hypoxia 
or oncogene signaling which stimulates endothelial cell 
migration and proliferation (Fig. 1) [7]. VEGF along with 
other factors recruit tumor-associated macrophages and 
other factors including chemokine (C–C motif) ligand 2 
(CCl2) chemokine (C–C motif), ligand 5 (CCL5), colony-
stimulating factor 1 (CSF-1), endothelins (ET-1) and trans-
forming growth factor beta (TGF-β) which stimulate cancer 
cell proliferation, invasion and angiogenesis [7].
The mutated form of endothelial growth factor recep-
tor (EGFRvIII) supports chronic proliferation by enabling 
cells to reprogram their cellular metabolism to keep up 
with high energy demands [8]. In virus-induced cancers 
and some non-viral etiology cancers, cells have the abil-
ity to evade destruction by immune cells, especially, T- and 
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Introduction
For 2015, 1.658 million new cancer cases and 589,430 
deaths were predicted worldwide and, according to the 
National Cancer Registry (NCR), more than 100,000 South 
Africans are annually diagnosed with cancer with a sur-
vival rate of 60 % [1, 2].
Cancer refers to abnormal growth or malignant tumors 
and is characterized by uncontrolled proliferation of cells 
despite restriction of nutrients and space [3]. Cancer cells 
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B-lymphocytes, natural killer cells and macrophages [9, 
10]. These cancer cells may secrete immunosuppressive 
factors such as TGF-β, or block interferon gene transcrip-
tion or their promoters [3]. In addition, tumor cells recruit 
cells that are actively immunosuppressive, such as regula-
tory T cells, or suppress capsid protein production and sub-
sequently immune cell detection [9]. Current cancer treat-
ment includes an array of treatment options and regimens 
that are specific for each cancer type. Treatment efficacy 
has inter-individual variability which will be discussed 
below.
Overview of current treatment
Current cancer treatments that are quite common include 
chemotherapy, radiation and surgery. Another less estab-
lished treatment is immunotherapy, where biotherapy 
results in the increased recognizability of cancer cells by 
immune cells [11]. Immunotherapy includes cancer vac-
cines (either prophylactic or therapeutic vaccines) that 
reprogram memory T cells and increase cancer autologous 
(Ag)-specific effector T cells in vivo [12]. Targeted thera-
pies are specifically aimed at cancer-associated molecules. 
These include rituximab (Rituxan®) and ibritumomab 
(Zevalin®) that target anti-CD20 antibodies on non-Hodg-
kins lymphoma cells [13].
Antimitotic drugs inhibit polymerization dynamics of 
microtubules (paclitaxel and vinblastine) by activating 
the spindle assembly checkpoint (SAC) blocking transi-
tion from metaphase to anaphase [14]. Subsequently, cells 
undergo mitotic arrest and since the compound disrupts 
spindle formation and chromosome orientation, cells 
remain either in a prolonged arrest state with subsequent 
apoptosis induction or in a senescence-like G1 state [15]. 
Microtubules are formed during interphase and are vital for 
correct chromosome segregation and cell division under-
going mitosis [16]. Microtubule dynamics is faster during 
mitosis compared to interphase, and thus microtubules are 
an ideal drug target since cancer cells possess hyperprolif-
erative activity [16].
Mechanism of action of antimitotic drugs
Drugs that act on microtubules can be divided into two 
groups according to their mechanism of action as either 
microtubule-destabilizing agents or microtubule-stabilizing 
agents [17]. Destabilizing drugs inhibit the polymeriza-
tion of microtubules when administered at high concentra-
tion [18]. Most destabilizing drugs bind to either the vinca 
domain or taxoid-binding domain [16]. Those that bind to 
the vinca domain found in the interface between β- and 
α-tubulin (called vinca alkaloids) include vinflunine, vin-
cristine, vinorelbine, vindesine and eribulin [19, 20]. Those 
that bind to the colchicine domain include cryptophycins, 
dolastatins and combretastatin-A4 [21, 22]. Drugs that 
enhance microtubule polymerization when administered 
at high concentrations, stabilize microtubules and pre-
vent Ca2+- or cold-induced depolymerization, and subse-
quent disassembly, include eribulin, spongistatin, rhizoxin, 
maytansinoids second- and third-generation taxanes, 
epothilones, ixabepilone and many others [16, 23]. Taxa-
nes, epothilones and many others belonging to this group 
Fig. 1  Cancer cells have the ability to evade anti-proliferating signals 
sent from surrounding tissues, sustain proliferative signals and avoid 
cell death which enable continuous replication, active metastasis and 
invasion and induce angiogenesis. Images were created using Micro-
soft® PowerPoint® 2013 software Pty/Ltd
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bind to the inner surface of the microtubule at a taxoid-
binding site on β-tubulin [16, 23]. Compounds that bind 
to an overlapping non-vinca and non-taxoid site on drug-
resistant βII- and βIII-tubulin isotypes include the microtu-
bule-stabilizing drugs; peloruside A (PLA) and laulimalide 
(undergoing pre-clinical study) [24]. PLA and laulimalide 
binding results in a mitotic arrest at the G2/M phase of the 
cell cycle and subsequently cell death [24]. Another char-
acteristic that makes these compounds superior to taxanes 
and vinca alkaloids is that they are poor substrates of P-gp 
drug efflux pumps [25, 26].
Cell cycle targets
Cell cycle control is maintained by cyclin-dependent pro-
tein kinases (Cdks) which are activated when binding to 
cyclin proteins [27]. Different cyclin proteins are expressed 
at different stages of the cell cycle and form cyclin-Cdk 
complexes that initiate growth, mitosis and cytokinesis 
depending on the cyclin being expressed (Fig. 2) [28].
Cyclin/Cdk activity is regulated by factors including 
the DNA-binding transcription factors elongation factor 
2 1-8 (E2F 1-8) and pocket proteins produced by the ret-
inoblastoma tumor suppressor gene (pRB) responsible for 
the synthesis of cyclin proteins, cyclin-dependent kinase 
inhibitors (Cdki), phosphorylation status, proteolysis via 
ubiquitylation and subcellular localization in the nucleus or 
cytosol [28]. Cyclin D transcription is activated by growth 
factors and combines with cyclin-dependent protein kinase 
4 (CDK4) [28]. The activation of Cdk4, when in complex 
with cyclin D, activates the E2F transcription system that 
aids in the induction of events resulting in DNA synthesis 
at the interface of the G1 and S phase [29]. After DNA rep-
lication (S phase), the cell enters another growth phase, G2, 
and activation of the cyclin B/Cdk1 complex induces entry 
into mitosis [28]. Two major interfaces exist within the cell 
cycle, namely the G1/S- and G2/M phase. Metaphase-to-
anaphase interface is ensured by checkpoints including cell 
dimension and nutrient availability, DNA replication, DNA 
damage and spindle attachment [28].
Spindle assembly
Accurate chromosome segregation during mitosis is 
ensured by feedback control via the spindle assembly 
checkpoint [31]. Correct spindle formation occurs when 
the sister kinetochores are connected to microtubules from 
opposite poles resulting in a bi-oriented chromosome or 
amphitelic attachment [31]. Incorrect chromosome segre-
gation may result in aneuploidy and chromosome instabil-
ity which is a characteristic of many aggressively prolifer-
ating tumors [32].
When a spindle fiber attaches to the kinetochore on a 
chromatid, the mitotic checkpoint complex (MCC) senses 
the tension between connected kinetochores and spindle 
fibers, as well as the lack of tension across unattached kine-
tochores and non-amphitelic attachments [33]. Unattached 
kinetochores signal MCC to inhibit anaphase-promoting 
complex/cyclosome (APC/C) [34]. The unattached kine-
tochore is then activated by Aurora kinase B and the active 
kinetochore recruits mitotic arrest deficient 1 (Mad1), bud-
ding uninhibited by benzimidazole (bub1) and multipolar 
spindle 1 (MPS1) [34, 35]. Aurora kinase B also modulates 
the Rod-Zwilch Zw10 (RZZ) complex which is involved in 
the recruitment process of Mad1 [31]. Mad1 binds to the 
unattached kinetochore and recruits mitotic arrest deficient 
2 (Mad2) in closed formation resulting in the formation 
of more Mad2 proteins in a closed formation from Mad2 
proteins in an open conformation [36]. The Mad2 proteins 
(closed formation) form a complex with mitotic check-
point serine/threonine protein kinase Bub1 beta (BubR1), 
mitotic arrest deficient 3 (Mad3) and budding uninhibited 
by benzimidazole 3 (Bub3) resulting in cell-division cycle 
protein 20 (Cdc20) inhibition via phosphorylation and sub-
sequently cannot bind to the anaphase-promoting complex 
cyclosome (APC/C) nor activate the mitotic proliferat-
ing factor (MPF) or degrade securing [37]. The cell enters 
mitotic arrest until proper spindle attachment has occurred 
at metaphase, and dynein is activated [27, 30]. Dynein is 
a motor protein that removes the MCC complex from the 
Fig. 2  Cell cycle control by the expression of growth factors (green), 
primarily in the G1 phase. Internal cell cycle signaling regulates the 
expression of different cyclin proteins (white arrows) at different 
stages of the cycle. Images were created using Microsoft® Power-
Point® 2013 software Pty/Ltd
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attached kinetochore [38]. Cdc20 is thus no longer inhib-
ited, and active cdc20 is ubiquitinated by APC [27, 30]. 
Cdc20 activation of APC/C degrades securin (a protein 
responsible for the inhibition of the protein separase) via 
ubiquitination [39]. Separase cleaves and deactivates cohe-
sion allowing sister chromatids to dissociate from one 
another and the cell enters anaphase [40].
Antimitotic drugs activate the spindle assembly check-
point (SAC), since they disrupt microtubule formation and 
chromosome segregation resulting in the characteristic 
mitotic arrest [15]. Since the compounds are disruptive to 
the correct attachment of microtubules, the cells undergo 
cell death via apoptosis [15].
Apoptosis
Apoptosis (adenosine triphosphate-dependent form of cell 
death) may occur through four different pathways, namely 
the intrinsic-, extrinsic-, endoplasmic reticulum-induced 
and the perforin/granzyme pathway [40].
The intrinsic pathway is usually governed by the B-cell 
lymphoma protein 2 (Bcl-2) protein family that can either 
be pro- or anti-apoptotic [41]. Pro-apoptotic proteins of the 
Bcl-2 family include Bcl-2-associated x protein (Bax), BH3 
interacting domain death agonist (bid), Bcl-2 antagonist of 
cell death (Bad), Bcl interacting protein (Bim), Bcl-2 inter-
acting killer (Bik), Bik-like killer protein (Blk) and snf 
B-cell lymphoma protein 10 (Bcl10) [41]. Bcl-2 proteins 
are responsible for mitochondrial membrane disruption and 
are regulated by tumor suppressor p53 [42]. Pores form in 
the mitochondrial membrane resulting in the reduction of 
the electrochemical gradient across the membrane [43]. 
The water-soluble heme protein, cytochrome complex (Cyt 
c) and serine protease Htr A2/Omi are transported from 
within the mitochondria through the disrupted outer mem-
brane into the cytosol increasing effector caspases activity 
[44]. Cyt c binds apoptotic protease activating factor (Apaf-
1) and cysteinyl aspartic acid-protease 9 (procaspase 9), 
thereby activating procaspase 9 [41].
In human cancer, defects in the control of apoptosis that 
lead to the protection of cancer cells to apoptotic stimuli 
are critical in tumor development [45]. Overexpression of 
anti-apoptotic or pro-survival proteins of the Bcl family 
such as Bcl 2, B-cell lymphoma-extra large (Bcl-xL), mye-
loid cell leukemia 1 (Mcl-1), Bcl-2-like protein 2 (BCL2L2 
or Bcl-w) and Bcl-2-related protein A1 (A1/Bfl-1) has been 
reported to be present in cancer [45]. Overexpression of 
each of these above-mentioned proteins is associated with 
different tumor types, for example Bcl-xL in multiple mye-
loma and Bcl-w in gastric cancer cells [46, 47]. Bcl-2 over-
expression occurs in 90 % of colorectal cancer, 80 % of 
B-cell lymphomas, 70 % of breast and 30–60 % of prostate 
cancer [48]. The tubulysin analog, KEMTUB10, binds 
tubulin at the vinca domain inhibiting tubulin polymeriza-
tion [49]. KEMTUB10 triggers apoptosis in MCF-7- and 
MDA-MB-231 cells by p53 upregulation and downregula-
tion of Bim [49]. Bcl-2 overexpression confers cancer cell 
resistance pertaining to taxanes and, since KEMTUB10 
does not prominently rely on Blc-2 phosphorylation to 
induce apoptosis, the compound is less susceptible to 
acquired Bcl-2 resistance [49].
The extrinsic pathway involves transmembrane receptors 
that form part of the tumor necrosis factor (TNF) recep-
tor gene superfamily called death receptors [41]. Death 
receptors and their corresponding ligands are fatty acid 
synthetase receptor (FasR) and fatty acid synthase ligand 
(FasL), tumor necrosis factor receptor 1 (TNF R1) and 
tumor necrosis factor alpha (TNF-α), death receptor (DR) 3 
and Apo3 ligand (Apo3L), DR4 and Apo2L, and DR5 and 
Apo2L [50]. When these receptor-ligand complexes form, 
cytoplasmic adaptor proteins are recruited, including Fas-
associated death domain (FADD) in the case of the FasL-
RasR complex and TNF receptor-associated death domain 
(TRADD) in the case of the TNF-α-TNFR1 complex [51, 
52]. The latter results in death-inducing signaling complex 
(DISC) formation, subsequent activation of caspase 8 and 
the induction of the execution pathway [53]. The execution 
pathway is induced by the activation of executioner caspase 
3 and subsequent DNA degradation, chromatin condensa-
tion, cell shrinkage, apoptotic body formation and mem-
brane blebbing [41].
The taxane taxol induces the extrinsic pathway by upreg-
ulating Aurora-A (Aur-A) which phosphorylates FADD at 
S203 and subsequently induces DISC formation in human 
cervical adenocarcinoma cell line (Hela), human gastric 
adenocarcinoma cell line (AGS) and human colorectal 
adenocarcinoma cell line (HTC15) [54]. Aur-A phospho-
rylation of FADD at S203 allows for FADD S203A phos-
phorylation by polo-like kinase 1 (Plk1) [54]. The double-
phosphorylated FADD (FADD-DD) also dissociates from, 
and subsequently activates, receptor-interacting serine/
threonine protein (RIP1) inducing the caspase-independent 
apoptotic pathway [54]. Several above-mentioned proteins 
including Bcl-2 and p53 are involved in another cell death 
and survival pathways, namely autophagy that will be dis-
cussed below.
Autophagy
Autophagy is a form of cell death where organelles and 
proteins are degraded resulting in energy that is packaged 
into double membrane vesicles known as autophagosomes 
[56]. Autophagic vesicles are transported along micro-
tubule tracks fusing with lysosomes for degradation and 
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recycling [55]. Autophagic pathways are upregulated when 
non-tumorigenic cells have a higher energy demand, such 
as nutrient deprivation, resulting in a stress state [55]. Can-
cer cells are resistant to autophagy by shrinking and enter-
ing a reversible dormant state when highly stressed due to 
the upregulation of autophagy by stressors such as starva-
tion and chemotherapeutic drugs [55]. Through this mecha-
nism, autophagy has been shown to support the survival of 
late stage or established tumors [3, 55].
Autophagic vesicles are transported by means of micro-
tubules. Antimitotic drugs, disrupting the microtubule for-
mation, result in vesicle accumulation, since they inhibit 
their fusion with lysosomes and thus their degradation and 
substrate recycling [55].
The taxane paclitaxel has been reported to inhibit 
autophagy in MCF-7 (a tumorigenic estrogen receptor-
positive (+) cell line) and SK-BR-3 breast cancer cells 
that have entered mitosis by blocking the class III phos-
phatidylinositol 3-kinase vacuolar protein sorting protein 
34 (Vps34), a protein vital in induction of autophagosome 
formation [55]. In MCF-7 and SK-BR-3 cells that were not 
undergoing mitosis because of mitotic slippage, paclitaxel 
prevented autophagy by hindering autophagosome traffick-
ing [55].
Classes of antimitotic drugs
Taxanes
Taxanes are commonly used as chemotherapy treatment 
for breast cancer [57]. The taxane paclitaxel (taxol®) used 
in combination with carboplatin (an alkylating agent that 
has cytotoxic activity) is a common treatment regimen for 
Table 1  Classes of antimitotic drugs and their stages of development [25, 26, 58, 61, 65, 67, 70, 71, 83, 85, 105–107]
Class Name Mechanism of action Approved for treatment of (cancer type)
Drugs used as cancer treatment regimens
 Taxanes Paclitaxel (taxol®) Microtubule-stabilizing Metastatic adenocarcinoma of the pancreas (in combina-
tion with gemcitabine)
Cabazitaxel (Jextana®) Microtubule-stabilizing Metastatic, hormone-resistant prostate cancer (in combi-
nation with prednisone)
 Epothilones Ixabepilone (Ixempra®) Microtubule-stabilizing Metastatic or locally advanced breast cancer (resistant to 
taxanes and anthracycline)
 Vinca  
alkaloids
Eribulin (E7389, ER086526, 6) Microtubule-destabilizing Recurrent metastatic breast cancer (pre-treated with  
taxanes and anthracycline)
Class Name Mechanism of action Phase of clinical trials
Drugs undergoing clinical trials
 Vinca alkaloids Vintafolide (EC145) Microtubule-destabilizing In Clinical phase II trials as sole treatment for 
ovarian and lung cancer
Class Name Mechanism of action Model
Drugs undergoing in vivo studies
 Non-taxoid site microtubule- 
stabilizing agents
Peloruside A (PLA, CHEBI:77692) Microtubule-stabilizing Lung and breast tumor xenograft 
studies in athymic nu/nu mice
Laulimalide Microtubule-stabilizing High toxicity and low tumor inhi-
bition in human breast cancer 
and fibrosarcoma xenograft 
studies in athymic NCr-nu/nu 
mice
Class Name Mechanism of action Effective in cell line
Drugs undergoing in vitro studies
 Estrogen derivatives ESE-15-ol Microtubule-destabilizing Breast cancer (MCF-7, MDA-
MB-231) and lung cancer (A549)
ESE-16 Microtubule-destabilizing Breast cancer cell lines (MCF-7, 
MDA-MB-231) and esophageal 
cancer (SNO)
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lung carcinoma (Table 1) [58]. Paclitaxel inhibits microtu-
bule depolymerization by binding to β-tubulin, resulting in 
mitotic arrest and subsequent activation of caspase-depend-
ent apoptosis by Bcl-2 proteins [56]. Taxanes usually 
increase the patients’ survival in carcinoma of the lung, 
breast and ovaria. However, taxanes are also associated 
with side effects, namely peripheral neuropathy, myelosup-
pression, arthralgias and skin reactions including flushes 
and rashes (urticarial) [58, 59]. Since these side effects 
accumulate throughout the course of therapy and affect the 
patient’s quality of life, adjunctive medications are required 
to minimize subsequent side effects [57].
Efficacy of taxanes as adjuvant therapy in early breast 
cancer is unclear [57]. Data of one clinical trial suggest 
that an addition of paclitaxel to anthracycline (an antibiotic 
class of chemotherapy that is cell-cycle non-specific) was 
only beneficial for women who had an overexpression of 
the human epidermal growth factor receptor 2 (HER2) in 
tumors of early breast cancer [57]. HER2 signaling influ-
ences multiple forms of taxane resistance including cell 
survival, as well as drug efflux and drug metabolism [60].
Cabazitaxel (Jextana®), a new microtubule-stabilizing 
taxane has been effective against metastatic breast- and 
metastatic hormone-resistant prostate cancer that acquired 
resistance to both paclitaxel and docetaxel [61]. Cabazi-
taxel has been improved by decreasing multidrug-resistant 
protein recognition for the compound and in turn reducing 
potential cancer cell resistance [61]. The antimitotic drug 
was approved for the treatment of metastatic, hormone-
resistant prostate cancer in Europe (March 2011) (Table 1) 
[62]. Side effects of cabazitaxel include nausea, diarrhea, 
vomiting and neurotoxicity [61].
Epothilones
Epothilones A and B were initially found in mycobacte-
rium sorangrum cellulosum as cytotoxic metabolites that 
stabilize microtubules. Epothilones show higher cytotoxic-
ity than taxanes in vitro [63]. For example, epothilone B 
shows a higher cytotoxicity to human ovarian cancer cells 
(OV-90) when compared to paclitaxel [64]. Epothilone B 
competitively inhibits paclitaxel, since both bind at the 
same site on tubulin-β [64]. However, epothilones and 
taxanes show no common mechanisms of resistance [64]. 
Epothilones are effective in cancers overexpressing class 
III β-tubulin where taxane resistance is attributable to the 
overexpression of class III β-tubulin [64].
Ixabepilone (Ixempra®) is a lactam analog of epothilone 
B (Table 1) [63]. The compound was approved by the USA 
in 2007 for use in the treatment of metastatic or locally 
advanced breast cancer that is resistant to taxanes and 
anthracycline [65]. The agent was the first epothilone to 
be approved for clinical use. Ixabepilone is metabolically 
more stable than its precursor, epothilone B, and thus the 
most clinically advanced epothilone with regards to its effi-
cacy and tolerability in breast cancer patients [63]. Ixabepi-
lone cytotoxicity is decreased cell lines expressing P-gly-
coprotein (P-gp), namely Madin-Darby canine kidney cells 
transfected with the human multidrug resistance 1 gene 
(MDCK-MDR1) and pig kidney epithelial cells transfected 
with the human multidrug resistance 1 gene (LLCPK-
MDR1) [66]. The latter thus confirms that ixabepilone is 
a substrate of the ATP-binding cassette efflux transporter, 
P-glycoprotein (P-gp/MDR1/ABC1) such as taxane class 
[66]. However, ixabepilone is not a substrate of the breast 
cancer resistance protein (BCRP1/ABCC-2), a protein 
that is significantly overexpressed in doxorubicin- and 
paclitaxel-resistant breast cancer cells (MCF-7/DOX and 
MCF-7AX), which explains the potency of ixabepilone- in 
taxane-resistant breast cancer [66].
Vinca alkaloids
The first vinca alkaloids were extracted from the plant 
catharamthus roseus, native to Madagascar, and were found 
to possess anticancer activities in 1960 [20]. Vina alkaloids 
include vincristine which was approved as chemotherapy 
treatment in 1963 in the USA [20]. These compounds bind 
to β-tubulin close to the guanosine triphosphate (GTP)-
binding sites (the vinca domain) at the β-α-tubulin het-
erodimers interface [20]. Binding at the vinca domain 
prevents curved tubulin from straightening and, in turn, 
interferes with growth and assembly of microtubules [67]. 
Eribulin (E7389, ER086526, 6), a compound derived from 
marine sponge, was approved in 2010 in the USA as the 
third-line treatment for patients with recurrent metastatic 
breast cancer (pre-treated with taxanes and anthracycline) 
(Table 1) [20, 67]. However, treatment was accompanied 
with neutropenia and fatigue, and the lower occurrence of 
peripheral neuropathology compared to older drugs is a 
potential benefit of eribulin [68]. Unfortunately, the drug is 
a substrate for the P-gp efflux pump and may demonstrate 
decreased activity against cancer cells that overexpressed 
these efflux pumps [69]. Vintafolide (EC145) has recently 
shown promise in ovarian and lung cancer during phase II 
clinical trials as sole treatment (Table 1) [70, 71]. The com-
pound consists of the microtubule-destabilizing agent desa-
cetylvinblastine hydrazide, folic acid, a hydrophilic peptide 
spacer and a disulfide-containing self-immolative linker 
[72]. Vintafolide delivers the microtubule-destabilizing 
agent to the folate receptors (FR) of FR-tumor cells [72]. 
FR is overexpressed in various carcinomas and mediates 
the uptake of folic acid-conjugated compounds via endo-
cytosis [73]. Once vintafolide is taken up in the cell, the 
disulfide bond is cleaved and active desacetylvinblastine 
hydrazide diffuses through the endosome to the cytoplasm 
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where it causes microtubule disruption [74]. Since FR is 
expressed in small amounts in non-tumorigenic tissues it is 
an ideal tumor target [73].
Microtubule‑targeting estrogen derivatives
Estrogen aids in the growth, differentiation and mainte-
nance of many tissues in the body including breast, uterine, 
cardiovascular, brain and urogenital tract tissues of both 
sexes by activating the nuclear estrogen receptors (ER), 
ERα and ERβ, to induce transcription factor activation [75, 
76]. In various types of cancer, especially breast and ovar-
ian cancer, estrogen is known to promote proliferation and 
invasion [75]. The goal for using estrogen-derived antican-
cer compounds is to compete with estrogen for the binding 
to estrogen receptors (ER) with antagonistic activity [75]. 
Fulvestrant (ICI182780) is an example of such a compound 
and shows to be more effective when compared to tamox-
ifen, the current non-steroidal anti-estrogen compound used 
as standard hormone treatment for breast cancer [75, 77].
In postmenopausal woman, estrone sulfate is found 
in high concentrations in breast tissue (3.3 ± 1.9 pmol/g 
vs. premenopausal woman 1.2 ± 0.3 pmol/g) and more 
so in patients with breast carcinoma [76–79]. The con-
centration of estrone sulfate is up to seven times higher 
in breast tissue than in plasma and is converted to estra-
diol sulfate in hormone-dependent breast cancers via the 
17-β-hydroxysteroid dehydrogenase type 1 enzyme [79, 
80]. The majority of breast cancer begins as a hormone-
dependent cancer where estradiol plays a vital role in tumor 
growth and development [81].
2‑Methoxyestradiol and in silico‑designed analogs
2-Methoxyestradiol (2ME), an analog of 17-β estra-
diol, occurs naturally in the human body and exerts anti-
mitotic activity [44]. 2ME binds at the colchicine domain 
of β-tubulin in microtubules resulting in microtubule 
depolymerization [44, 82]. At low concentrations, 2ME 
destabilizes microtubules and impairs correct spindle-
kinetochore attachment; the cell subsequently undergoes 
cell death as a result of prolonged mitotic arrest [82]. The 
17-hydroxy group pertaining to 2ME makes it a target for 
17-hydroxysteroid dehydrogenase-mediated metabolism 
(in the gastrointestinal tract (GIT) and liver) resulting in 
rapid metabolism and subsequent low bioavailability [83]. 
2-Ethyl-3-O-sulfamoyl-estra-1,3,5(10)15-tetraen-17-ol 
(ESE-15-ol), 2-ethyl-3-O-sulfamoyl-estra-1,3,5(10)16-
tetraene (ESE-16) and 2-ethyl-3-O-sulfamoyl-estra-
1,3,5(10),15-tetraen-3-ol-17-one are sulfamoylated analogs 
of 2ME and have been in silico designed in order to selec-
tively bind to and inhibit carbonic anhydrase IX (CAIX) 
in vitro [83, 85]. CA IX, a zinc membrane-bound enzyme, 
is upregulated in most types of cancer and acidifies the 
extracellular environment by converting carbon dioxide and 
water to carbonic acid [86]. Acidification of the cancerous 
environment promotes further metastasis and invasion [83]. 
The acidification of the extracellular environment may also 
lead to chemoresistance, since the uptake of weakly basic 
anticancer drugs is decreased by the formation of a H+ gra-
dient across the cellular membrane [86].
CAIX is also involved in cellular migration and inva-
sion of human cervical carcinoma cells (C33A) in vitro 
[87]. In non-tumorigenic physiological conditions, this 
metalloenzyme is only found in a few non-tumorigenic 
tissues such as coelomic epithelial cells, basal cells in 
and around hair follicles, gastric mucosa cells and cells 
in the ventricular lining of the choroid plexus [86, 88]. 
During carcinogenesis, the expression of CAIX in these 
tissues is either reduced or lost [86]. Since CAIX is pre-
dominantly expressed in carcinomas from non-tumori-
genic tissues that do not express CAIX, it is an ideal pro-
tein marker for cancer [86]. The upregulation of CAIX is 
induced by hypoxia via the transcription factor, hypoxia-
inducible factor-1 (HIF-1) [84]. 2ME inhibits HIF-1 tar-
get gene expression in tumor cells at the posttranscrip-
tional level [88]. The alpha subunit of HIF (HIF-1α) is 
overexpressed in many human cancers [89]. 2ME blocks 
accumulation of HIF-1α in the nucleus and in turn pre-
vents activation of several genes that are crucial for cell 
transformation and survival under hypoxic conditions 
[89].
Modifications to the chemical structures of these com-
pounds, including the addition of a sulfamoylated group 
or the removal of a hydroxyl group, increase the bioavail-
ability of these compounds as it prevents first pass metabo-
lism by the liver [44, 85, 90]. In addition, this modification 
allows these compounds to bind to carbonic anhydrase II 
(CAII) in red blood cells, resulting in a slower release of 
these compounds into the bloodstream and in turn avoid-
ing first pass metabolism [85]. These characteristics allow 
ESE-15-ol and ESE-16 to be potentially more effective 
than their rapidly metabolized precursor 2ME [83–85]. An 
increase in G1 phase (an indication of cell death via DNA 
damage), a decrease in mitochondrial membrane potential 
(an indication of apoptosis via the intrinsic pathway) and 
G2/M arrest, followed by disrupted spindle formation or the 
formation of multiple spindle poles, are events induced by 
ESE-15-ol and ESE-16 [83–85]. MDA-MB-231, a meta-
static tumorigenic estrogen receptor-negative cell line, 
MCF-7 and MCF-12A, a non-tumorigenic estrogen recep-
tor-negative (−) cell line, were used for evaluation. A gen-
eral 50 % inhibition of cellular growth was seen across the 
three cell lines at nanomolar concentrations after 24 and 
48 h exposure periods, proving the compounds are more 
potent than 2ME in vitro [83–85]. The compounds also had 
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a reduced effect on the non-tumorigenic cell line, MCF-
12A (−), when compared to the tumorigenic cell lines that 
are exposed to ESE-15-ol, and this was especially evident 
after 48 h [83–85].
In both ESE-15-ol and ESE-16 exposed cells, there was 
a disruption in phosphorylation of the pro-apoptotic bind-
ing protein, Bcl-2, at serine 70 in the MDA-MB-231 (−) 
cell line, indicating activation of apoptosis via the intrinsic 
pathway, corresponding with the decrease in mitochondrial 
membrane potential observed [83–85]. The studies thus 
demonstrated that these compounds possess potential as 
antimitotic agents with respect to potency and bioavailabil-
ity in vitro (Table 1) [83–85].
Cancer cell resistance to antimitotic compounds
Resistance to antimitotic drugs can occur at different stages 
of treatment, and the comprehension of these resistance 
mechanisms is vital in the development of novel antimitotic 
compounds [16]. Genetic changes that exist prior to treat-
ment are the first cause of therapeutic failure of chemo-
therapy, and this is known as intrinsic or primary resistance 
[91]. Secondary or acquired resistance is a result of drug 
treatment [91].
One mechanism developed by tumor cells, when 
exposed to chemotherapy including antimitotic drugs 
in vitro, is the membrane efflux pumps of the ATP-
binding cassette (ABC) family [16]. These transporters 
export the compounds that have accumulated within the 
cells through the cellular membrane avoiding toxicity of 
the drugs [16]. The multidrug resistance gene 1 (MDR1 
or ABCD1) is responsible for the production of P-gp, 
part of the ABC family, which effluxes many hydropho-
bic antimitotic drugs such as taxanes and vinca alkaloids 
[16, 92]. ABCD1 and P-gp overexpression is involved in 
both intrinsic drug resistance and acquired drug resist-
ance [91]. The multidrug-associated protein 1 (MRP1) 
transports vinca alkaloids out of the cell [16]. MRP2 
and MRP7 are responsible for the export of taxanes and 
MRP7 for the transport of epothilone B [16]. Expression 
of these efflux pumps shows a correlation with a lower 
response to antimitotic chemotherapy in primary tumors 
[16]. Thus, developing drugs that are not substrates of 
P-gp, such as second- and third-generation taxanes and 
epothilones, whose structural modifications allow them 
to avoid P-gp, are essential to overcome the obstacles of 
cancer resistance [92]. Another strategy is to make use of 
molecules, where the activity is strengthened by overex-
pressed P-gp efflux pumps [91]. It has been reported that 
combination treatment of a multidrug-resistant breast can-
cer cell line (MCF-7/ADR) with paclitaxel and the P-gp 
inhibitor Verapamil had a synergistic effect on cytotoxic-
ity in vitro [93].
Mutations in p53 gene expression, activating muta-
tions of phosphatidyl-3-phosphate kinase (PI3 K) and gene 
expression of the Ras/Raf pathway all have been reported 
to result in increased resistance to antimitotic drugs in 
tumor cells [94]. Hypomethylation of phosphatase and 
tensin homolog deleted from chromosome 10 (PTEN), a 
tumor suppressor gene, destabilizes the gene and results in 
the upregulation of the phosphatidylinositol 3-kinase/Akt 
kinase (PI3 K/Akt) pathway, which activates Akt, a pro-
tein that regulates anti-apoptotic proteins and cell cycle 
entry resulting in survival signaling [91]. The loss of PI3 K 
regulation increases Bad phosphorylation, resulting in the 
deactivating of the pro-apoptotic protein and subsequently 
protects the mitochondrial membrane from disruption 
[94]. This increases resistance to cell death induced by 
the intrinsic pathway. The overexpression of the mitogen-
activated protein kinase cascade (Ras/Raf/MAPK) path-
way, where Ras (a small GTP kinase receptor) activates 
MAPK, results in the activation of Raf. Mutations of these 
genes that upregulate this pathway lead to survival signal-
ing [91].
The overexpression of class III β-tubulin isotope, a 
marker used in the diagnosis of solid tumor malignan-
cies such as ovarian and lung cancer, is suspected of being 
responsible for resistance to paclitaxel [95]. βIII-tubulin 
enhances microtubule dynamic instability and counteracts 
the stabilizing action of taxanes [17]. It also affects the effi-
cacy of vinca alkaloids [91]. βIII-tubulin is expressed in 
stressed cells deprived of oxygen and nutrients [91]. The 
expression of βIII-tubulin is a survival pathway, that, when 
inhibited in nude mice, increases the sensitivity of cells 
to chemotherapy, but also inhibits colony formation and 
the development of tumorigenesis [17]. Mutations in the 
β-tubulin gene in vitro and in patients also seem to contrib-
ute to drug resistance, specifically antimitotic compounds 
[94]. Regulating proteins of microtubules such as mitotic 
centrosome-associated kinesin (MCAK), stathmin and tau 
are associated with antimitotic drug resistance [91]. Dereg-
ulation of proteins of the SAC via gene amplification such 
as the protein Aurora kinase via AURORA-A amplification 
also contributes to resistance in drugs that target microtu-
bules [96].
HER2 signaling activates the transcription factor Y-box-
binding protein-1 (YBX), and in turn increases survival, 
reduces induction of apoptosis and enhances drug efflux 
[97, 98]. A positive feedback loop exists between HER2 
and YBX that promotes further cancer cell immortality 
[91]. Thus, HER2 overexpression results in increasingly 
aggressive tumors and HER2-amplified cancer types pose 
resistance to taxanes by regulating P-gp efflux pumps [60]. 
The latter is accomplished by means of survivin, which is 
crucial in spindle assembly formation, and cyclin-depend-
ent kinase inhibitor 1A (P21CIP1) that inhibits cell cycle 
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progression at G1 [60]. Augmentation of HER2 occurs in 
20–25 % of breast cancer types, and HER2-targeted therapy 
(trastuzumab and lapatinib) has been reported to increase 
life expectancy by 50 %. Reoccurrence after treatment is a 
major obstacle faced in the clinic, and the mechanisms of 
resistance to these compounds have not yet been confirmed 
[99]. Another factor influencing resistance is hypoxia, com-
monly found in the center of solid tumors [100]. Hypoxia 
potentially reduces drug access and efficacy [100]. This 
oxygen-deprived state in tumors influences cell cycle con-
trol signaling pathways and angiogenesis and increases 
invasion and metastasis [100]. Hypoxia also inhibits the 
intrinsic pathway of apoptosis by reducing the Bax/Bcl-2 
ratio [100]. Since an increase in resistance due to hypoxia 
in the presence of paclitaxel is reversed by increased cyclin 
B1 levels, hypoxia reduces the antimitotic activity of pacli-
taxel by downregulation of cyclin B1 [100].
The non-coding microRNAs is another gene expression 
regulator found both over- and under expressed in several 
types of cancer including breast, prostate, lung, gastric, 
colon, ovarian cancer and leukemia. MicroRNA confers 
cancer cell resistance to antimitotic drugs since it regulates 
various genes involved in the cell proliferation, differentia-
tion and apoptosis [101]. miR-125b is overexpression in 
taxol-resistant breast cancer cells, 435TRP and metastatic 
breast cancer cells, MDA-MB-231. miR-125b targets Bcl-2 
antagonist killer 1 (Bak1), a pro-apoptotic protein, and 
confers resistance to antimitotics such as paclitaxel [102]. 
MicroRNAs also target Bcl-2, Bax, Bcl-xL and caspase 
3 and 7 expression leading to the disruption of apoptosis 
[101]. Other microRNAs, such as miR-27, regulates the 
multidrug resistance 1 gene (MDR1) increasing drug efflux 
transporters (P-gp) and, in turn, confers resistance to its 
substrates including taxanes and vinca alkaloids [101].
The theory that antimitotic drugs target and kill cancer 
cells, because of their high proliferation rate in vitro, is 
contradicted with the low doubling time of tumor cells, 
such as primary breast cancer (40–300 days) and meta-
static breast cancer (30–90 days) [15, 103]. To date, the 
mechanisms of anticancer drugs have predominantly 
been evaluated in cancer cell lines in vitro and mouse 
models with deficient immunity [104]. These models 
restrict research from determining the influence of these 
drugs on actual human tumor physiology, since they lack 
a representation of the immune system and vasculature 
[104]. This may lead to several action mechanisms going 
undetected.
Conclusion
Antimitotic drugs such as the taxane cabazitaxel (Jextana®) 
(accepted in 2011), and the vinca alkaloid vintafolide 
(EC145, phase II), show promise in taxane and anthracy-
cline-resistant cancers [71]. However, the toxicity of these 
drugs, as well as acquired drug resistance, allows for the 
opportunity to develop agents with increased tolerability 
and specificity [58, 59]. Development of novel compounds 
that disrupt mitosis without interfering with microtubule 
dynamics in non-dividing or highly proliferating (such as 
neutrophils) non-tumorigenic cells is the main focus in 
new antimitotic drug research. The in silico-designed 2ME 
analogs show promise since they were designed to target 
CAIX in the tumorigenic environment, increasing the bioa-
vailability which will be evaluated in vivo in the near future 
[83–85].
Studies investigating the pathways of cancer cell resist-
ance to antimitotic drugs will result in subsequent identi-
fication of novel biomarkers for future chemotherapy pos-
sessing increased efficacy. However, the limited success 
of antimitotics in clinical trials is mainly due to antimi-
totic targeting mechanisms varying substantially between 
in vitro and in vivo models since the drug resistance is 
poorly understood. In addition, unraveling the role of 
mitotic machinery and identifying the determinants of drug 
resistance in different models will contribute to the embed-
ded scientific knowledge regarding antimitotic efficacy and 
subsequently yield novel biochemical targets for improved 
chemotherapy.
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